Relation between serological data at the time of biopsy and renal histology in lupus nephritis

Nossent, Jiri; Henzen‐Logmans, S. C.; Vroom, Thea M.; Huysen, V.; Berden, Jo H. M.; Swaak, A. J. G.

doi:10.1007/bf00291150

Cited by 33 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, one study [9] reported an association with lupus nephritis, whereas another study [11] concluded that there was an association with active nephritis only. We set out to test the hypothesis that IgA anti-dsDNA antibodies are associated with disease activity and clinical manifestations of SLE in a large population of SLE patients.…”

Section: Introductionmentioning

confidence: 97%

Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus

Witte

Hartung

Tenbusch³

et al. 1998

Rheumatology International

View full text Add to dashboard Cite

Previously it has been suggested that the presence of antibodies against dsDNA of the IgA class may define a subset of systemic lupus erythematosus (SLE) patients suffering from nephritis and arthritis. Therefore, these autoantibodies were measured in sera of 352 patients with SLE, 81 blood donors, and 189 patients with rheumatoid arthritis using a new ELISA based on human recombinant dsDNA as antigen. IgA anti-dsDNA antibodies were found in 19.9% of the sera from patients with SLE, but in none of the sera from 81 normal controls and 189 patients with rheumatoid arthritis. The association of these autoantibodies with 31 clinical and 36 laboratory parameters was calculated. IgA anti-dsDNA antibodies were found to be associated with parameters of disease activity such as elevated erythrocyte sedimentation rate and consumption of complement component C3, and the clinical parameters vasculitis, with necrosis and erythema, but not with nephritis and arthritis. Therefore, IgA anti-dsDNA antibodies define a subset of SLE patients, and monitoring of IgA anti-dsDNA antibodies may be helpful as a prognostic parameter in patients with SLE.

show abstract

Section: Introductionmentioning

confidence: 97%

Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus

Witte

Hartung

Tenbusch³

et al. 1998

Rheumatology International

View full text Add to dashboard Cite

show abstract

“…Silent LN has been reported not only in class II but also in class IV (62)(63)(64)(65)(66)(67)(68). Even patients with low-level proteinuria (,1 g/24 h) have demonstrated significant renal involvement with proliferative LN (classes III or IV) (69,70).…”

Section: Clinicopathologic Correlationsmentioning

confidence: 99%

Lupus Nephritis

Giannico

Fogo

2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryMost patients with SLE develop kidney disease related to this systemic underlying disease process. Lupus nephritis is an important cause of morbidity and even mortality in patients with systemic lupus erythematosus. Lupus nephritis has diverse morphologic manifestations with varying clinical presentations and consequences. The pathogeneses involve immune complexes, which can deposit anywhere in the kidney, and other mechanisms, including endothelial injury, podocytopathy, and tubulointerstitial injury. Treatment and prognosis accordingly range from excellent even with only observation with minimal mesangial deposits, to kidney failure despite aggressive immunosuppression in patients with severe proliferative disease. Renal biopsy plays a crucial role in the diagnosis of the specific form of lupus nephritis in any patient. However, the role of the renal biopsy in prediction of outcome, treatment, and prognosis has been controversial. We will review the current classification of lupus nephritis and the value of renal biopsy in the management of these patients.

show abstract

“…eases such as SLE (2,3), mixed connective tissue disease (4) and Sj6gren's syndrome (5). Some authors addressed the possible role of IgG-and IgM-aCL as indicators of clinical activity in SLE (3,(6)(7)(8)(9). However, it remains uncertain in which rheumatic diseases and under what conditions monitoring of aCL is clinically useful.…”

Section: Introductionmentioning

confidence: 97%

Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases

et al. 1997

View full text Add to dashboard Cite

The prevalence of anticardiolipin antibodies in active systemic lupus erythematosus (SLE) was compared with that in inactive SLE and other rheumatic and non-rheumatic diseases to determine the value of these autoantibodies in monitoring rheumatic diseases. Pairs of IgG- and IgM-aCL were measured by ELISA in 173 consecutive hospitalised patients, including 141 with rheumatic diseases (18 active SLE, 21 inactive SLE, 19 rheumatoid arthritis, 13 reactive arthritis, 7 other spondyloarthropathies, 16 vasculitis, 47 other autoimmune diseases) and 32 non-rheumatic controls. A further 101 aCL pairs were determined during follow-up in 19 patients with SLE. Serum concentrations were analysed with respect to SLE activity and compared between the different patient groups. IgG- and IgM-aCL levels in excess of 10 GPL and 9 MPL respectively were considered positive. 30.6% of all patients (53/173) were found to be positive for IgG-aCL, as against only 9.8% (17/173) for IgM-aCL. IgG-aCL serum levels in active SLE differed significantly from all other groups, including inactive SLE (all p < 0.005). Median IgM-aCL levels were below the cut off point in all groups, although measurable values were obtained almost exclusively in active SLE and RA. In this study IgM-aCL measurement was of less value in monitoring rheumatic diseases. IgG-aCL positivity in SLE was associated with a significantly higher odds ratio (OR) for active disease (OR 16.0, 95% confidence interval: 2.8-90.0). The results show that disease activity in SLE was accompanied by significantly increased IgG-aCL, whereas no elevation was found in other diseases. This parameter may therefore be useful in monitoring SLE activity.

show abstract

Relation between serological data at the time of biopsy and renal histology in lupus nephritis

Cited by 33 publications

References 34 publications

Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus

Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus

Lupus Nephritis

Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases

Contact Info

Product

Resources

About